National Comprehensive Cancer Network
124
16
23
73
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
19.4%
24 terminated/withdrawn out of 124 trials
75.3%
-11.2% vs industry average
1%
1 trials in Phase 3/4
77%
56 of 73 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (124)
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Role: collaborator
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Role: collaborator
Overcoming Racial Disparities in Screening Mammography
Role: collaborator
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Role: collaborator
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Role: collaborator
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
Role: collaborator
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Role: collaborator
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Role: collaborator
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Role: collaborator
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
Role: collaborator
Tivozanib + Enzalutamide in Adv Prostate Cancer
Role: collaborator
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Role: collaborator
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Role: collaborator
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Role: collaborator
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Role: collaborator
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Role: collaborator
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Role: collaborator
Increasing Adherence to Lung Cancer Screening
Role: collaborator
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Role: collaborator
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Role: collaborator